SANJAY DESHPANDE to Rituximab
This is a "connection" page, showing publications SANJAY DESHPANDE has written about Rituximab.
Connection Strength
0.094
-
Ibrutinib plus RICE or RVICI for relapsed/refractory mature B-cell non-Hodgkin lymphoma in children and young adults: SPARKLE trial. Blood Adv. 2023 02 28; 7(4):602-610.
Score: 0.048
-
Ibrutinib plus Bendamustine and Rituximab in Untreated Mantle-Cell Lymphoma. N Engl J Med. 2022 06 30; 386(26):2482-2494.
Score: 0.046